GlycoNex (ROCO:4168) Cyclically Adjusted Revenue per Share: NT$0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4168 GlycoNex Inc ROCO:4168
55 GF Score
Price NT$23.00
GF Value NT$71.29
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is GlycoNex Cyclically Adjusted Revenue per Share?

GlycoNex ROCO:4168 -1.08% 55 Cyclically Adjusted Revenue per Share is NT$0.00 as of Mar. 2026. GuruFocus rates ROCO:4168 with a GF Score™ of 55/100 and a GF Value™ of NT$71.29 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

GlycoNex's adjusted revenue per share for the three months ended in Mar. 2026 was NT$0.107. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$0.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, GlycoNex's average Cyclically Adjusted Revenue Growth Rate was 20.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -9.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of GlycoNex was -9.80% per year. The lowest was -33.30% per year. And the median was -21.55% per year.

As of today (2026-08-08), GlycoNex's current stock price is NT$23.00. GlycoNex's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was NT$0.00. GlycoNex's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GlycoNex was 343.59. The lowest was 51.76. And the median was 201.50.


GlycoNex  (ROCO:4168) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GlycoNex was 343.59. The lowest was 51.76. And the median was 201.50.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


GlycoNex Cyclically Adjusted Revenue per Share Related Terms


GlycoNex Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for GlycoNex's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlycoNex Cyclically Adjusted Revenue per Share Chart

GlycoNex Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.15 0.00 0.08 0.11

GlycoNex Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.11 0.11 0.11 0.00

ROCO:4168 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, GlycoNex's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlycoNex Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoNex's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where GlycoNex's Cyclically Adjusted PS Ratio falls into.


ROCO:4168
55GF Score
GlycoNex Inc ROCO:4168
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlycoNex Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GlycoNex's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.107/330.2130*330.2130
=0.107

Current CPI (Mar. 2026) = 330.2130.

GlycoNex Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.001 241.018 0.001
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.006 243.801 0.008
201706 0.001 244.955 0.001
201709 0.000 246.819 0.000
201712 0.001 246.524 0.001
201803 0.001 249.554 0.001
201806 0.005 251.989 0.007
201809 0.003 252.439 0.004
201812 0.003 251.233 0.004
201903 0.004 254.202 0.005
201906 0.002 256.143 0.003
201909 0.000 256.759 0.000
201912 0.003 256.974 0.004
202003 0.001 258.115 0.001
202006 0.001 257.797 0.001
202009 0.002 260.280 0.003
202012 0.001 260.474 0.001
202103 0.005 264.877 0.006
202106 0.003 271.696 0.004
202109 0.001 274.310 0.001
202112 0.046 278.802 0.054
202203 0.137 287.504 0.157
202206 0.152 296.311 0.169
202209 0.001 296.808 0.001
202212 0.016 296.797 0.018
202303 0.002 301.836 0.002
202306 0.015 305.109 0.016
202309 0.009 307.789 0.010
202312 0.000 306.746 0.000
202403 0.085 312.332 0.090
202406 0.001 314.175 0.001
202409 0.020 315.301 0.021
202412 0.029 315.605 0.030
202503 0.125 319.799 0.129
202506 0.147 322.561 0.150
202509 0.036 324.800 0.037
202512 0.040 324.054 0.041
202603 0.107 330.213 0.107

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$0.00 mean?
GlycoNex (ROCO:4168) has a Cyclically Adjusted Revenue per Share of NT$0.00 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on GlycoNex and its competitors.
Is GlycoNex's Cyclically Adjusted Revenue per Share too high?
GlycoNex's current Cyclically Adjusted Revenue per Share is NT$0.00. Overall, GlycoNex has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does GlycoNex's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
GlycoNex's Cyclically Adjusted Revenue per Share of NT$0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on GlycoNex and its competitors. GlycoNex's current Cyclically Adjusted Revenue per Share is NT$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlycoNex stock overvalued right now?
Based on GuruFocus' analysis, GlycoNex (ROCO:4168) is currently considered Possible Value Trap. The stock's GF Value™ is NT$71.29, compared to a current price of NT$23.00 — trading 67.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$0.00. GlycoNex's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For GlycoNex (ROCO:4168), the current Cyclically Adjusted Revenue per Share is NT$0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlycoNex (ROCO:4168) Overvalued in 2026?

Based on GuruFocus' analysis, GlycoNex stock appears to be undervalued. The current stock price of NT$23.00 is trading 67.7% below its estimated GF Value™ of NT$71.29. GuruFocus considers GlycoNex to be Possible Value Trap.

Key valuation signals for ROCO:4168:

  • Cyclically Adjusted Revenue per Share: NT$0.00
  • GF Value™: NT$71.29 vs. price of NT$23.00 (67.7% below fair value)
  • GF Score™: 55/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4168 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GlycoNex Business Description

Address Section 1, Xintai 5th Road, 8th Floor, No. 97, Xizhi District, New Taipei City, TWN, 221
GlycoNex Inc is a Taiwan-based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies that targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability, and can serve as reagents with applications that include ELISA, Western blot, flow cytometry, and TLC immunostaining. The other services provided by the firm include functional evaluation, antibody research, and antibody engineering. It has two reportable segments: antibody new drug, which derives maximum revenue, and exclusive investment. Geographically, the group derives maximum revenue from Taiwan and the rest from Japan.
55GF Score

Get the complete analysis for ROCO:4168

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$23.00
Price
NT$71.29
GF Value